Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MIW815 + Spartalizumab |
Synonyms | ADU-S100 + Spartalizumab |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MIW815 | ADUS100|ADU-S100|NVP-MIW815 | STING1 Agonist 19 | MIW815 (ADUS100) is a synthetic cyclic dinucleotide that acts as an activator for the stimulation of interferon gene signaling (STING1), resulting in T cell differentiation and infiltration of the tumor, thereby possibly resulting in tumor regression (PMID: 28483787, PMID: 31355488). | |
Spartalizumab | PDR001|PDR-001 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03172936 | Phase I | MIW815 + Spartalizumab | Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Terminated | USA | NLD | ESP | DEU | CHE | CAN | AUS | 1 |